New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 12, 2014
07:05 EDTVSTMVerastem announces initiation of COMMAND study in Japan
Verastem announced the expansion of its ongoing COMMAND study to include clinical trial sites in Japan. COMMAND is a registration-directed trial evaluating the Company’s lead candidate targeting cancer stem cells, VS-6063, a potent inhibitor of focal adhesion kinase, in patients with malignant pleural mesothelioma. With the inclusion of Japan, COMMAND is now accruing patients and pursuing parallel clinical development in the major markets worldwide.
News For VSTM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 27, 2015
08:28 EDTVSTMVerastem weakness overdone, says JMP Securities
After Verastem reported that 24% of the KRAS-mutated NSCLC patients in a study of its FAK inhibitor defactinib had experienced serious adverse events, JMP Securities notes that it did not ascribe any valuation for the drug as a treatment for this indication. Moreover, the firm does not believe that the study affects the outlook for the drug in other settings, and it says that, given the patients' late stage status, deaths among the participants "would not be seen as an anamoly." JMP adds that the drug met its primary endpoint in the study. JMP reiterates a $23 price target and Outperform rating on the shares.
August 26, 2015
16:26 EDTVSTMOn The Fly: Top stock stories for Wednesday
Subscribe for More Information
15:16 EDTVSTMVerastem says VS-6063 results under embargo, believes study has met goals
Verastem issued the following statement in response to inquiries regarding the anticipated oral presentation of VS-6063 data from a Phase 2 study in patients with KRAS mutant non-small cell lung cancer, or NSCLC, at the 16th World Conference on Lung Cancer: "While updated results from the Phase 2 study of VS-6063 in KRAS mutant non-small cell lung cancer are under embargo until WCLC, Verastem believes the study has met its goals, with encouraging outcomes that the company plans to explore in future studies. The population explored in this study has refractory, advanced lung cancer, with a median of three prior therapies, and as many as eight prior therapies. The advanced stage of disease led, in some cases, to deaths even in the period between screening and prior to first dose of VS-6063. Two subjects reported as having grade 5 respiratory failure were on multiple concomitant medications and presented with multiple co-morbidities. Both were thoroughly evaluated and reported to the regulatory authorities in 2013 and 2014 when they occurred. The totality of safety and efficacy data seen to date with VS-6063 across multiple clinical trials, multiple tumor types and stages of treatment is promising. In addition, in the company's registration-directed COMMAND trial in mesothelioma, an independent data safety monitoring board has met and reviewed study data, including adverse events, three times and recommended no changes to study protocol. There have been over 300 patients treated to date with VS-6063, including patients on drug for more than one year. Verastem remains encouraged by the clinical potential of targeting cancer stem cells through FAK inhibition, and is unwavering in its commitment to delivering novel, safe and effective treatments to patients with unmet medical needs."
11:55 EDTVSTMVerastem safety concerns on NSCLC data misplaced, says Mizuho
Subscribe for More Information
11:43 EDTVSTMVerastem selloff on 'placeholder' abstract ignores key driver, says Roth Capital
Subscribe for More Information
10:51 EDTVSTMVerastem shares defended at Roth Capital
Subscribe for More Information
09:24 EDTVSTMVerastem to present data at World Conference on Lung Cancer
Subscribe for More Information
August 20, 2015
05:48 EDTVSTMMizuho keeps TESARO, Verastem, OncoMed as top biotech picks
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use